1. Home
  2. RDHL vs ADXN Comparison

RDHL vs ADXN Comparison

Compare RDHL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDHL
  • ADXN
  • Stock Information
  • Founded
  • RDHL 2009
  • ADXN 2002
  • Country
  • RDHL Israel
  • ADXN Switzerland
  • Employees
  • RDHL N/A
  • ADXN N/A
  • Industry
  • RDHL Biotechnology: Pharmaceutical Preparations
  • ADXN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDHL Health Care
  • ADXN Health Care
  • Exchange
  • RDHL Nasdaq
  • ADXN Nasdaq
  • Market Cap
  • RDHL 8.2M
  • ADXN 8.0M
  • IPO Year
  • RDHL N/A
  • ADXN N/A
  • Fundamental
  • Price
  • RDHL $5.36
  • ADXN $7.06
  • Analyst Decision
  • RDHL
  • ADXN Strong Buy
  • Analyst Count
  • RDHL 0
  • ADXN 1
  • Target Price
  • RDHL N/A
  • ADXN $30.00
  • AVG Volume (30 Days)
  • RDHL 10.1K
  • ADXN 17.9K
  • Earning Date
  • RDHL 04-07-2025
  • ADXN 03-24-2025
  • Dividend Yield
  • RDHL N/A
  • ADXN N/A
  • EPS Growth
  • RDHL N/A
  • ADXN N/A
  • EPS
  • RDHL N/A
  • ADXN 0.06
  • Revenue
  • RDHL $3,707,000.00
  • ADXN $701,260.00
  • Revenue This Year
  • RDHL $224.90
  • ADXN N/A
  • Revenue Next Year
  • RDHL $82.69
  • ADXN N/A
  • P/E Ratio
  • RDHL N/A
  • ADXN $0.92
  • Revenue Growth
  • RDHL N/A
  • ADXN N/A
  • 52 Week Low
  • RDHL $5.20
  • ADXN $6.73
  • 52 Week High
  • RDHL $20.28
  • ADXN $27.90
  • Technical
  • Relative Strength Index (RSI)
  • RDHL 34.07
  • ADXN 42.98
  • Support Level
  • RDHL $5.52
  • ADXN $6.73
  • Resistance Level
  • RDHL $5.71
  • ADXN $7.90
  • Average True Range (ATR)
  • RDHL 0.29
  • ADXN 0.51
  • MACD
  • RDHL -0.03
  • ADXN -0.07
  • Stochastic Oscillator
  • RDHL 10.31
  • ADXN 16.34

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Share on Social Networks: